New Trial Suggests CV Benefit With EPA: RESPECT-EPA
Although the open-label trial has many limitations, it could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose eicosapentaenoic acid.
Medscape Medical News
source https://www.medscape.com/viewarticle/983621?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/983621?src=rss
Comments
Post a Comment